A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 84
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : CE
Long Form : conjugated estrogens
No. Year Title Co-occurring Abbreviation
2019 Conjugated Estrogens and Bazedoxifene Improve beta Cell Function in Obese Menopausal Women. AIRg, BZA, DI, Gb, MHT, T2D
2019 Effects of bazedoxifene/conjugated estrogens on reproductive endocrinology and reproductive tract ultrasonographic appearance in premenopausal women: a preliminary study. BZA, TSEC
2019 Effects of conjugated estrogen and bazedoxifene on hemostasis and thrombosis in mice. BZA, TSEC
2018 Estrogens Promote Misfolded Proinsulin Degradation to Protect Insulin Production and Delay Diabetes. ER, ERAD, ERalpha, T2D
2018 Long-Term Administration of Conjugated Estrogen and Bazedoxifene Decreased Murine Fecal beta-Glucuronidase Activity Without Impacting Overall Microbiome Community. BZA, GUS
2018 What do TSECs provide in the menopausal hormone therapy? BZA, MHT, SERM, TSEC
2017 The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights. BZA, ERs, SERMs
2017 The Tissue-Selective Estrogen Complex (Bazedoxifene/Conjugated Estrogens) for the Treatment of Menopause. BZA, SERM, TSEC
2016 Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials. BMD, BZA, MENQOL, SMART
10  2016 Effect of selective estrogen receptor modulators on metabolic homeostasis. BZA, ER, SERMs, TSEC
11  2016 Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium. BZA, FGF, HAND2
12  2015 A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials. BZA, HDL-C, LDL-C, PBO, SMART, TC
13  2015 Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial. BZA, MPA, SMART
14  2015 Effects of genistein in combination with conjugated estrogens on endometrial hyperplasia and metabolic dysfunction in ovariectomized mice. GEN, SERM, TSEC
15  2015 Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide. BZA, EPT, HT, SMART, VMS
16  2014 Bazedoxifene and conjugated estrogen prevent diet-induced obesity, hepatic steatosis, and type 2 diabetes in mice without impacting the reproductive tract. BZA, SERM
17  2014 Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms. BZA, HRQoL, HT, TSEC
18  2014 Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy. BZA
19  2014 Continuous high-dose estrogen controls serum FSH and LH levels: new treatment strategy for extremely low ovarian reserve patients, two case reports. LOR, POI
20  2014 Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss. BZA, EPT, SERM, TSEC
21  2014 Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. AE, BMD, BZA, MPA, PBO, SMART
22  2014 Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling. BZA, VMS
23  2014 Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens. BZA, CFA, CIDs, HRQoL, MENQOL
24  2014 Reproductive senescence blunts response of estrogen receptor-alpha expression to estrogen treatment in rat post-ischemic cerebral microvessels. ERalpha, RS
25  2014 Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial. BZA, HRQoL, MENQOL, MPA
26  2014 Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model. BZA, PgR, SERM, TSEC
27  2013 Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. BZA
28  2013 Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens. BZA
29  2013 Effect of oviductus ranae and oviductus ranae eggs on bone metabolism and osteoporosis. ALP, BGP, BMD, OR, ORE, TRAP
30  2013 Global profiling of TSEC proliferative potential by the use of a reporter mouse for proliferation. IHC, SERMs
31  2013 Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model. BZA, SERM, TSEC
32  2013 Tissue-selective estrogen complexes for postmenopausal women. BZA, EPT, SERM, TSEC
33  2012 Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy. BZA, SMART
34  2012 The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms. BMD, BZA, SERM, SMART, TSEC
35  2012 The tissue selective estrogen complex: a promising new menopausal therapy. BZA, EPT, SERM, TSEC, VVA
36  2012 Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review. BZA
37  2011 Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE). BZA, BZA/CE, SERM, TSEC
38  2011 Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. BMD, BZA, TSEC
39  2010 A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. BZA, SMART-3, VVA
40  2010 Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. ASEX, BZA, MENQOL, MS-TSQ, TSEC
41  2010 Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. BZA, LAS, RAL, SERM
42  2009 Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. VMI
43  2009 Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. BZA
44  2009 The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women. MPA
45  2008 Ethnic differences in levels of bone and cartilage biomarkers and hormonal responsiveness in nine groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study. BMI, HT, MPA, PAM
46  2008 Hormone profiles of mares affected by the mare reproductive loss syndrome. CL, MRLS
47  2008 The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. ER, ET
48  2007 Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial. BC, BW, FBM, HOPE, LBM, MPA, PBF
49  2007 Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: the Pan-Asia Menopause (PAM) study. HDL-C, LDL-C, MPA, PAM
50  2007 Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study. MPA, PAM
51  2007 Uterine development in Turner syndrome. HRT, OC, TS
52  2006 Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. MENQOL, MPA, PAM
53  2006 Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. CR, SHBG
54  2005 Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. BMD, MPA, Women's HOPE
55  2005 Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. MPA, PAM
56  2005 Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. MPA, PAM, VMI, VMS
57  2005 Use of postmenopausal hormone therapy since the Women's Health Initiative findings. PHT, RDD, SSRIs, WHI
58  2004 Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT. AI, ER, MPA, NETA, PR
59  2004 Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. BMD, BMI, MPA, Women's HOPE
60  2004 Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. ---
61  2004 Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins. HRT, LDL, MPA, NETA, TC, TG
62  2004 Long-term effects of two different continuous combined regimens of hormone replacement therapy on well-being. HRT, MPA, NETA, PMS
63  2003 Intravenous estrogens increase insulin clearance and action in postmenopausal women. CON, EST, SSGIR
64  2003 The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. MRS, SERM
65  2001 Modulation of coronary flow velocity reserve by gender, menstrual cycle and hormone replacement therapy. CFVR, TTCDE
66  2000 Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. ERT, HRT
67  2000 The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. HRT, MPA
68  1999 Estradiol-17beta measurement in women receiving conjugated estrogens. Dissociation between two commercial methods. HRT
69  1998 Conjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation. CTEG, OLT
70  1998 Effects of different hormone replacement regimens on postmenopausal women with abnormal lipid levels. Menopause Study Group. HDL2, LDL, MPA
71  1997 Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. IP
72  1996 Correcting prolonged bleeding during renal transplantation with estrogen or plasma. FFP
73  1995 Estrogens reduce plasma histidine-rich glycoprotein (HRG) levels in a dose-dependent way. EE, HRG, OC
74  1995 The effect of medrogestone on plasma lipids and lipoproteins in postmenopausal women using conjugated estrogens: an open randomized comparative study. apo, HDL, LDL
75  1994 The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. ERT, HRT, PAI, TAT
76  1992 Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. OGTT
77  1986 Benefits and risks of different hormonal replacement therapies in post-menopausal women. CPA, HDL, LDL, NET
78  1986 Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharges in cats. ---
79  1985 Estrogen and progestin effects on urinary calcium and calciotropic hormones in surgically-induced postmenopausal women. DMPA, PM
80  1985 Sex steroids modulate prolactin response to naloxone in postmenopausal women. MPA, PRL
81  1985 The effects of estrogen and progestin on endogenous opioid activity in oophorectomized women. beta-EP, LF, ML, MPA, NAL, Pre
82  1982 The effects of estrogen on adrenal androgens in oophorectomized women. AA, ACTH, DHEA, OO, OV
83  1981 Conjugated estrogens and breast cancer risk in women. RR
84  1975 The effects of antiepileptic drugs on estrogen-induced electrographic spike-wave discharge. ---